Kisha Marie Farrell, APRN FNP-BC Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 119 W Main St, Hominy, OK 74035 Phone: 918-885-4640 Fax: 918-885-4644 |
Mary Kekahbah, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 129 Conner Rd, Hominy, OK 74035 Phone: 918-594-1300 |
Stephanie Ann Durham, AGNP-C Nurse Practitioner - Adult Health Medicare: Accepting Medicare Assignments Practice Location: 119 W Main St, Hominy, OK 74035 Phone: 918-885-4640 Fax: 918-885-4644 |
Lindsey Hester, APRN, FNP, ENP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 119 W Main St, Hominy, OK 74035 Phone: 918-885-4640 Fax: 918-885-4644 |
Mrs. Joyce Julia White, FNP, ARNP Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 115 S Price Ave, Hominy, OK 74035 Phone: 918-885-1264 Fax: 918-885-1265 |
Wendy Denise Madison, CNP Nurse Practitioner - Primary Care Medicare: Accepting Medicare Assignments Practice Location: 119 W Main St, Hominy, OK 74035 Phone: 918-885-4640 Fax: 918-885-4644 |
News Archive
Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.
Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced today that the U.S. Food and Drug Administration (FDA) has cleared for marketing the CARTOXPRESS™ Software Module and the LASSO® NAV Circular Mapping Catheter for use with the CARTO® XP Mapping System.
Depressed teenagers who received cognitive behavioral therapy in their primary care clinic recovered faster, and were also more likely to recover, than teens who did not receive the primary care-based counseling, according to a Kaiser Permanente study published today in the journal Pediatrics.
Merck announced today that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted unanimously that the available data support approval of Merck's investigational medicine VICTRELIS™ (boceprevir) for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 infection in combination with current standard therapy.
› Verified 5 days ago